Epidermal growth factor (EGF) plays an important role in tumorigenesis. The association between the +61 A/G polymorphism of the EGF gene and colon cancer risk remains controversial and unclear. The objective of this study was to investigate the association between EGF +61 A/G polymorphism and colon cancer risk in a Chinese population. A hospital-based case-control study was conducted to assess the possible association between EGF +61 A/G polymorphism and colon cancer risk. A total of 180 colon cancer patients and 180 cancer-free healthy controls were recruited in the Chinese population. Genomic DNA was isolated from peripheral blood, and gene polymorphisms were analyzed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Colon cancer patients had a significantly higher frequency of +61 GG genotype (odds ratio [OR]=1.93, 95% confidence interval [CI]=1.07, 3.50; p=0.03) than that of controls. When stratified by the tumor location, tumor size, growth pattern, differentiation, and tumor-node-metastasis (TNM) stage of colon cancer, no statistically significant results were observed. Our study revealed that EGF +61 GG genotype was associated with a higher risk of colon cancer in Chinese population.

Download full-text PDF

Source
http://dx.doi.org/10.1089/gtmb.2012.0109DOI Listing

Publication Analysis

Top Keywords

colon cancer
32
+61 a/g
16
a/g polymorphism
16
cancer risk
12
egf +61
12
chinese population
12
epidermal growth
8
growth factor
8
colon
8
cancer
8

Similar Publications

Colorectal cancer is the fourth leading cause of cancer-related deaths worldwide. Capecitabine is a chemotherapeutic agent commonly used for the treatment of colon cancer. To realize local sustained release, promote efficient local intracellular transport, and mitigate the systemic toxic effects of capecitabine, a capecitabine prodrug, capecitabine-poly (p-dioxanone) (Cap-PPDO), was successfully synthesized.

View Article and Find Full Text PDF

A previously reported clinical trial in familial adenomatous polyposis (FAP) patients treated with erlotinib plus sulindac (ERL + SUL) highlighted immune response/interferon-γ signaling as a key pathway. In this study, we combine intermittent low-dose ERL ± SUL treatment in the polyposis in rat colon (Pirc) model with mechanistic studies on tumor-associated immune modulation. At clinically relevant doses, short-term (16 weeks) and long-term (46 weeks) ERL ± SUL administration results in near-complete tumor suppression in Pirc colon and duodenum (p < 0.

View Article and Find Full Text PDF

Background: Hospice palliative care is used as a last resort to relieve the clinical symptoms of elderly colon cancer patients. The nurse is a key participant in the overall care process. However, little is known about hospice palliative care from a nursing perspective.

View Article and Find Full Text PDF

Circulating Markers of Systemic Inflammation, Measured After Completion of Neoadjuvant Therapy, Associate With Response in Locally Advanced Rectal Cancer.

Dis Colon Rectum

March 2025

Academic Unit of Surgery, School of Cancer Sciences, College of Medical, Veterinary & Life Sciences, University of Glasgow, New Lister Building, Glasgow Royal Infirmary, Glasgow, United Kingdom.

Background: The extent of neoadjuvant therapy response, prior to surgery, is an important prognosticator in locally advanced rectal cancer. A spectrum of response exists, with a dearth of reliable measurements. The host response to treatment remains unexplored.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!